Acute viral nasopharyngitis cost-effectiveness of therapy

Acute viral nasopharyngitis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating acute viral nasopharyngitis from other diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X-ray
CT
MRI
Ultrasound
Other imaging findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Acute viral nasopharyngitis cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Acute viral nasopharyngitis cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
National Guidelines Clearinghouse
NICE Guidance
FDA on Acute viral nasopharyngitis cost-effectiveness of therapy
CDC on Acute viral nasopharyngitis cost-effectiveness of therapy
Acute viral nasopharyngitis cost-effectiveness of therapy in the news
Blogs onAcute viral nasopharyngitis cost-effectiveness of therapy
Directions to Hospitals Treating Osteoporosis
Risk calculators and risk factors for Acute viral nasopharyngitis cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Cost Effectiveness of Therapy

• In the USA alone, the common cold leads to 75-100 million physician visits annually, at a conservative cost estimate of $7.7 billion per year.
• Americans spend $2.9 billion on over-the-counter drugs and another $400 million on prescribed medicines, both for symptomatic relief.
• More than one-third of patients who saw a doctor received an antibiotic prescription, not only contributes to unnecessary costs ($1.1 billion annually on an estimated 41 million antibiotic prescriptions in the United States), but also has implications for antibiotic resistance.
• An estimated 22-189 million school days are missed annually due to a cold. As a result, parents missed 126 million workdays to stay home to care for their children. When added to the 150 million workdays missed by employees suffering from a cold, the total economic impact of cold-related work loss exceeds $20 billion.